Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 727 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Lung Small Cell Carcinoma Clear all
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674
View directory record Official record
Conditions
Lung Cancer
Interventions
PR104, F-18-fluoromisonidazole
Drug · Other
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Tucson, Arizona • Beverly Hills, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00009971
View directory record Official record
Conditions
Lung Cancer
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 21, 2026, 9:51 AM EDT
Not listed Phase 2 Interventional

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

NCT00014547
View directory record Official record
Conditions
Lung Cancer
Interventions
BBR 3464
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
18
States / cities
Hoover, Alabama • Fayetteville, Arkansas • Berkeley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 1 Interventional

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

NCT05049863
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Mycophenolate Mofetil, Allopurinol, Irinotecan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

NCT04479306
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alisertib, Osimertinib, Sapanisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional Results available

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

NCT00096265
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
80
States / cities
Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT07355205
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00293280
View directory record Official record
Conditions
Lung Cancer
Interventions
lomustine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT00004186
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, ifosfamide, topotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

NCT00612677
View directory record Official record
Conditions
Lung Cancer
Interventions
Oxaliplatin, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pembrolizumab + Idelalisib for Lung Cancer Study

NCT03257722
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastasis, Recurrence
Interventions
Pembrolizumab, Idelalisib
Drug
Lead sponsor
Asha Nayak
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 21, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
356
States / cities
Scottsdale, Arizona • Modesto, California • Monterey, California + 231 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 21, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

NCT00698516
View directory record Official record
Conditions
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Interventions
Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 21, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

NCT06693336
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Interventions
SMS001
Drug
Lead sponsor
ToLymph Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00754923
View directory record Official record
Conditions
Lung Cancer
Interventions
sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 21, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

NCT02147990
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
41
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 21, 2026, 9:51 AM EDT